The story keeps going the same way. Veterans run out of options inside the system, find their way to a clinic outside it, and come back different. The data follows, eventually. This week the data showed up again.
What Stanford Just Published
A new preprint from Stanford's Brain Stimulation Lab, posted March 20 on bioRxiv, looked at what ibogaine actually does to the brain in veterans with PTSD and traumatic brain injury. The team — led by Malvika Sridhar and Azeezat Azeez with senior authors Manish Saggar and Nolan Williams — ran resting-state EEG on participants before treatment and at one month after. They used a frequency-decomposition method called FREQ-NESS to map how brain networks reorganize at specific frequencies, which is harder than it sounds and rare in psychiatric research.
The finding: high-beta networks around 24 to 25 Hz shifted away from frontal regions and toward posterior ones, both immediately post-dose and a month later. That posterior shift correlated with how much PTSD symptoms improved — the bigger the shift, the better the outcome. The same pattern showed up when the researchers ran the analysis on an independent dataset of ibogaine treatment for opioid use disorder. Two different patient populations, same neural signature. Neural field modeling traced the effect to changes in cortico-cortical wiring rather than thalamic loops, which narrows down what the drug is actually doing.
It builds on the same Stanford group's 2024 Nature Medicine paper, which reported an 88% reduction in PTSD symptoms in 30 combat veterans after a single magnesium-ibogaine session at a clinic in Mexico. Depression dropped 87%, anxiety 81%. Suicidal ideation went from 47% of the cohort down to 7%. None of those participants got the drug on US soil. Ibogaine is still Schedule I here, which is part of why this story keeps happening.
Why It Lands Now
The timing isn't accidental. On April 18 the White House signed an executive order accelerating federal review of psychedelics, naming ibogaine twice and committing $50 million toward it, with veterans framed as the primary beneficiaries. Utah passed HB 390 in March, authorizing a state-funded ibogaine study for veterans with treatment-resistant PTSD. Nine VA facilities — including the one in San Diego — are now running psychedelic-assisted therapy trials. Five years ago this would have been a press release nobody printed.
The Stanford paper matters because it does what regulators and skeptical clinicians have been asking for. It points at a mechanism. The drug isn't just making people feel better in vague psychospiritual ways. Something is reorganizing in the cortex, and the reorganization tracks with symptom relief. Frontal hyperactivity — the kind that shows up in chronic PTSD scans — is loosening its grip. Posterior, cortico-cortical connectivity is increasing. That's the kind of evidence the FDA actually moves on, and the kind that pulls a Schedule I substance toward a clinic instead of a courtroom.
None of this is permission to skip the rest of the work. The veterans who've gone through ibogaine tend to talk less about the dose itself and more about what came after — the therapy, the long quiet months of integration, the parts the brand pages never put in the carousel. But the science is catching up to what a small group of people already knew. The system, slow as it is, is finally building a way to let it in.
Sources:
- bioRxiv — Ibogaine is associated with reorganization of high-beta brain networks in veterans with PTSD
- Nature Medicine — Magnesium–ibogaine therapy in veterans with traumatic brain injuries
- Military.com — VA Expands Psychedelic Therapy Trials for PTSD
- NPR — Trump signs order fast tracking review of psychedelics
This post is editorial reporting. Nothing here is medical advice. Psychedelic compounds are controlled substances in most jurisdictions. If you're struggling, talk to a licensed professional.